Login to Your Account



Strong Phase II Resminostat Data Send 4SC Shooting Up

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, January 25, 2012
Shares in 4SC AG surged more than 38 percent last week on news that its histone deacetylase (HDAC) inhibitor resminostat hit the primary endpoint of a Phase II trial in advanced hepatocellular carcinoma (HCC).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription